AstraZeneca’s Imfinzi Flunks In Late-Stage Advanced Cervical Cancer Study
AstraZeneca Plc’s (NASDAQ:AZN) Imfinzi (durvalumab) and chemoradiotherapy did not achieve the primary goal of improving survival in patients with locally advanced…
Why Most Kids Did Not Suffer Badly Due To COVID-19 Infection? Scientists Look To Solve Mystery: CNBC
The COVID-19 pandemic has led to over 6 million fatalities. The scientists are still studying why most children do not suffer badly from coronavirus infection.
Bristol Myers Sues AstraZeneca Over PD-L1 Cancer Drug Patents
Bristol Myers Squibb Co (NYSE: BMY) claims that AstraZeneca Plc's (NASDAQ: AZN) PD-L1 inhibitor, Imfinzi, infringed on at least eight patents in a newly filed complaint.
AstraZeneca Highlights Preclinical EVUSHELDTM Data From Washington University Showing ‘EVUSHELD reduces viral burden of all tested Omicron subvariants in the lungs’
First in vivo data from Washington University show EVUSHELD reduces viral burden of all tested Omicron subvariants in the lungs
New preclinical authentic ‘live' virus data from Washington University School of
AstraZeneca Mulls Ditching US Approval For Its COVID-19 Vaccine: FT
Citing AstraZeneca Plc's (NASDAQ: AZN) head of research and development, the Financial Times reported that the Company
ImpediMed Announced AstraZeneca Extends and Increases Renal Contract
ImpediMed Limited (ASX.IPD), today announced the second contract extension and expansion of its SOZO Digital Health Platform used in clinical trials being conducted for AstraZeneca. The Phase II trial will use the SOZO devices to track patient fluid volume in an upcoming pharmaceutical study focused on chronic kidney disease.
Dynavax Adjuvanted Clover Bio’s COVID-19 Vaccine Booster Shows Durable Protection Against Omicron
Clover Biopharmaceuticals Ltd’s follow-up analysis for efficacy in the SPECTRA Phase 2/3 trial of SCB-2019 COVID-19 vaccine provided high and…
The Daily Biotech Pulse: AbbVie’s Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
AstraZeneca’s Evusheld Approved by UK Medicines and Healthcare products Regulatory Agency to Prevent COVID-19 in People Whose Immune Response is Poor
A new medicine, Evusheld (tixagevimab/cilgavimab), has today been authorised for COVID-19 prevention by the Medicines and Healthcare products Regulatory Agency (MHRA) after meeting the UK regulatory standards of safety, quality and effectiveness.